{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:52Z","timestamp":1791825352888,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In myasthenia gravis (MG), evidence on the impact of social determinants of health on disparities in disease burden and healthcare resource utilization is limited. This study aimed to investigate the independent association between race\/ethnicity and acute care utilization during the 2\u202fyears post-diagnosis among patients with MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective cohort study was conducted among adults (\u226518\u202fyears) with newly diagnosed MG in the United States using Optum\u2019s de-identified Market Clarity Data from January 1, 2010, to December 31, 2019. Multivariable regression models were used to assess the association between acute care utilization and race\/ethnicity, insurance, exacerbation at index, and other covariates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 7,058 patients met the study inclusion criteria, of whom 57% (<jats:italic>n<\/jats:italic>\u202f=\u202f4,052) identified as Caucasian, 6% (<jats:italic>n<\/jats:italic>\u202f=\u202f445) African American, 3% (<jats:italic>n<\/jats:italic>\u202f=\u202f235) Hispanic, 1% (<jats:italic>n<\/jats:italic>\u202f=\u202f94) Asian, and 32% (<jats:italic>n<\/jats:italic>\u202f=\u202f2,232) with missing race\/ethnicity information. Compared with patients identifying as Caucasian, those identifying as African American had 37% higher odds of having an emergency department visit in year 1, and those identifying as Hispanic had 70% increase in odds of having a hospitalization event in year 2 post-diagnosis. Among other covariates, Medicaid usage, exacerbation at index, and number of outpatient visits were significantly associated with acute care utilization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Racial disparities significantly impacted acute care utilization in the first 2\u202fyears post-MG diagnosis. Future studies should aim to examine specific factors that may contribute to disparities such as barriers to healthcare access, greater severity of MG symptoms, and poorly controlled disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1448803","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T17:34:26Z","timestamp":1738604066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Racial disparities in acute care utilization among individuals with myasthenia gravis"],"prefix":"10.3389","volume":"13","author":[{"given":"Cynthia","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushpa","family":"Narayanaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E. L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakshinamoorthy","family":"Amirthaganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J Neurol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"123264","DOI":"10.1016\/j.jns.2024.123264","article-title":"Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis","volume":"466","author":"Sarah","year":"2024","journal-title":"J Neurol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"17562864221150327","DOI":"10.1177\/17562864221150327","article-title":"Healthcare resource use in myasthenia gravis: a US health claims analysis","volume":"16","author":"Mahic","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/wnl.48.5.1253","article-title":"Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation","volume":"48","author":"Thomas","year":"1997","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1385\/NCC:3:3:213","article-title":"Risk of extubation failure in patients with myasthenic crisis","volume":"3","author":"Rabinstein","year":"2005","journal-title":"Neurocrit Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1147489","DOI":"10.3389\/fpubh.2023.1147489","article-title":"Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs","volume":"11","author":"Hughes","year":"2023","journal-title":"Front Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: a systematic literature review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e9184","DOI":"10.7759\/cureus.9184","article-title":"A review of psychiatric comorbidity in myasthenia gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The lived experience of myasthenia gravis: a patient-led analysis","volume":"10","author":"Law","year":"2021","journal-title":"Neurol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1247931","DOI":"10.3389\/fpubh.2023.1247931","article-title":"The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges","volume":"11","author":"Hughes","year":"2023","journal-title":"Front Public Health"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"822909","DOI":"10.3389\/fpubh.2022.822909","article-title":"Socio-economic burden of masthenia gavis: a cost-of-illness study in Bulgaria","volume":"10","author":"Ignatova","year":"2022","journal-title":"Front Public Health"},{"key":"ref16","year":"2013"},{"key":"ref17","year":"2023"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000524733","article-title":"Are there racial differences in inpatient outcomes and treatment utilization following hospitalization for myasthenia gravis exacerbation?","volume":"56","author":"Syed","year":"2022","journal-title":"Neuroepidemiology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/mus.21191","article-title":"Racial differences in myasthenia gravis in Alabama","volume":"39","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"553626","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of quality of life in myasthenia gravis patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11892-020-01369-x","article-title":"Diabetes complications in racial and ethnic minority populations in the USA","volume":"21","author":"Haw","year":"2021","journal-title":"Curr Diab Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40615-016-0335-8","article-title":"Racial\/ethnic disparities in diabetes quality of care: the role of healthcare access and socioeconomic status","volume":"5","author":"Canedo","year":"2018","journal-title":"J Racial Ethn Health Disparities"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0027-9684(15)30085-7","article-title":"Racial and ethnic disparities in diabetes complications in the northeastern United States: the role of socioeconomic status","volume":"105","author":"Osborn","year":"2013","journal-title":"J Natl Med Assoc"},{"key":"ref25","year":"2023"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.27526","article-title":"Validation of myasthenia gravis diagnosis in the older Medicare population","volume":"65","author":"Lee","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref27","first-page":"188","article-title":"Charlson comorbidity index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1111\/dom.14512","article-title":"Validation of obesity-related diagnosis codes in claims data","volume":"23","author":"Suissa","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref29","volume-title":"Thymectomy","author":"Bennett","year":"2024"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biomedicines11041227","article-title":"Health disparities in multiple sclerosis among hispanic and black populations in the United States","volume":"11","author":"Moore","year":"2023","journal-title":"Biomedicine"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1212\/WNL.0000000000004025","article-title":"Racial disparities in neurologic health care access and utilization in the United States","volume":"88","author":"Saadi","year":"2017","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000324935","article-title":"Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disability","volume":"36","author":"Dahodwala","year":"2011","journal-title":"Neuroepidemiology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/j.1532-5415.2006.00834.x","article-title":"Ethnic differences in expectations for aging among older adults","volume":"54","author":"Sarkisian","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s11606-008-0521-4","article-title":"Racial and ethnic disparities in the VA health care system: a systematic review","volume":"23","author":"Saha","year":"2008","journal-title":"J Gen Intern Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10823-014-9233-x","article-title":"Knowledge and attitudes about Parkinson's disease among a diverse group of older adults","volume":"29","author":"Pan","year":"2014","journal-title":"J Cross Cult Gerontol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1468-0009.2011.00619.x","article-title":"Dropping the baton: specialty referrals in the United States","volume":"89","author":"Mehrotra","year":"2011","journal-title":"Milbank Q"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"197893","DOI":"10.1155\/2015\/197893","article-title":"Gender and ethnicity based differences in clinical and laboratory features of myasthenia gravis","volume":"2015","author":"Abukhalil","year":"2015","journal-title":"Autoimmune Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","article-title":"Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey","volume":"11","author":"Mahic","year":"2022","journal-title":"Neurol Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref41","article-title":"Characteristics and healthcare utilization of patients with myasthenia gravis who developed excerbation","author":"Lin","year":"2023"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"809999","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large U.S. insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","article-title":"Employment in myasthenia gravis: a systematic literature review and meta-analysis","volume":"54","author":"Guastafierro","year":"2020","journal-title":"Neuroepidemiology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","article-title":"Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America registry analysis","volume":"60","author":"Harris","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"},{"key":"ref49","article-title":"Long-term healthcare source utilization and costs among patients with newly diagnosed myasthenia gravis: a Swedish nationwide population-based study","author":"Cai","year":"2023"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol Belg"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2155-9562.1000317","article-title":"Myasthenia gravis and its comorbidities","volume":"6","author":"Cacho Diaz","year":"2015","journal-title":"J Neurol Neurophysiol"},{"key":"ref52","first-page":"s321","article-title":"Impact of diagnosis and early treatment on the course of multiple sclerosis","volume":"19","author":"Noyes","year":"2013","journal-title":"Am J Manag Care"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"20552173221092411","DOI":"10.1177\/20552173221092411","article-title":"Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: a register-based prospective cohort study in Sweden","volume":"8","author":"Karampampa","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1212\/WNL.0000000000207664","article-title":"Association of Very Early Treatment Initiation with the risk of long-term disability in patients with a first demyelinating event","volume":"101","author":"Cobo-Calvo","year":"2023","journal-title":"Neurology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/jnnp-2022-330169","article-title":"Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study","volume":"94","author":"He","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/PPA.S101175","article-title":"The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review","volume":"10","author":"Ganguli","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"965229","DOI":"10.3389\/fpsyg.2022.965229","article-title":"A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: lessons from a consumer-based survey on adveva((R)) PSP","volume":"13","author":"Barello","year":"2022","journal-title":"Front Psychol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1448803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T17:34:29Z","timestamp":1738604069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1448803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":58,"alternative-id":["10.3389\/fpubh.2025.1448803"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1448803","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"article-number":"1448803"}}